^
Association details:
| Biomarker: | AR positive |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) + Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ceritinib is a novel triple negative breast cancer therapeutic agent
Published date:
06/29/2022
Excerpt:
The combination of ceritinib and enzalutamide showed a robust inhibitory effect on cell growth of AR+ TNBC cells in vitro and in vivo….The combination of paclitaxel and ceritinib showed drastic inhibition of tumor growth compared to a single drug alone....All agents used in our study are FDA-approved, and thus the proposed combination therapy will likely be useful in the clinic.
DOI:
10.1186/s12943-022-01601-0
